這是一項第二期／第三期隨機臨床試驗，評估放射敏感性輔助個人化自適應放射治療技術（RAPART）在局部晚期非小細胞肺癌患者中的應用。主要目標是測試在標準與非標準混合治療條件下，不可切除的第三期NSCLC相比於傳統治療在整體存活期（OS）、無惡化存活期（PFS）及局部無惡化存活期（LPFS）的整體改善。
適應症：Locally Advanced Non-small Cell Lung Cancer
收案條件
納入條件
- Adult research participants, aged over 18 years old;
- Non small cell lung cancer that requires pathological confirmation;
- All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
- ECOG physical condition is 0-2;
- In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.
排除條件
- Prisoners who are not convenient for close clinical follow-up;
- Study participants with contraindications to radiation therapy.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。